Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Pennsylvania doctor Neil Anand, MD, was convicted for illegally doling out "goody bags" of prescription drugs that patients ...

Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug ...

Key points include access to medicines in medicare is reduced as the IRA is implemented; fewer drugs are covered on Medicare ...

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030 ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

The Centres for Medicare and Medicaid Services (CMS) said late on Friday that it would not cover anti-obesity medicines (AOMs) like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...